These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 27876352)

  • 1. Quantitative analysis of pharmacokinetic profiles of verapamil and drug-drug interactions induced by a CYP inhibitor using a stable isotope-labeled compound.
    Kataoka M; Kojima C; Ueda K; Minami K; Higashino H; Sakuma S; Togashi K; Mutaguchi K; Yamashita S
    Drug Metab Pharmacokinet; 2016 Dec; 31(6):405-410. PubMed ID: 27876352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo characterization of CYP inhibition by 1-aminobenzotriazole in rats.
    Parrish KE; Mao J; Chen J; Jaochico A; Ly J; Ho Q; Mukadam S; Wright M
    Biopharm Drug Dispos; 2016 May; 37(4):200-11. PubMed ID: 26637499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding processes determine the stereoselective intestinal and hepatic extraction of verapamil in vivo.
    Thörn HA; Sjögren E; Dickinson PA; Lennernäs H
    Mol Pharm; 2012 Nov; 9(11):3034-45. PubMed ID: 23009633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin.
    Fromm MF; Busse D; Kroemer HK; Eichelbaum M
    Hepatology; 1996 Oct; 24(4):796-801. PubMed ID: 8855178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opposite effect of diabetes mellitus induced by streptozotocin on oral and intravenous pharmacokinetics of verapamil in rats.
    Hu N; Xie S; Liu L; Wang X; Pan X; Chen G; Zhang L; Liu H; Liu X; Liu X; Xie L; Wang G
    Drug Metab Dispos; 2011 Mar; 39(3):419-25. PubMed ID: 21135265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative Analysis of the Transporter-Mediated Drug-Drug Interaction Between Atorvastatin and Rifampicin Using a Stable Isotope-IV Method.
    Yamashita S; Hasegawa T; Tachihara M; Minami K; Higashino H; Togashi K; Mutaguchi K; Kataoka M
    J Pharm Sci; 2017 Sep; 106(9):2671-2677. PubMed ID: 28457720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of liver fibrosis on verapamil pharmacokinetics in rats.
    Chen M; Xu D; Hu XL; Wang H
    Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):287-94. PubMed ID: 17973928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of 1-aminobenzotriazole in differentiating the role of CYP-mediated first pass metabolism and absorption in limiting drug oral bioavailability: a case study.
    El-Kattan AF; Poe J; Buchholz L; Thomas HV; Brodfuehrer J; Clark A
    Drug Metab Lett; 2008 Apr; 2(2):120-4. PubMed ID: 19356080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance.
    Strelevitz TJ; Foti RS; Fisher MB
    J Pharm Sci; 2006 Jun; 95(6):1334-41. PubMed ID: 16625658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil.
    Eichelbaum M; Somogyi A; von Unruh GE; Dengler HJ
    Eur J Clin Pharmacol; 1981 Jan; 19(2):133-7. PubMed ID: 7202473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of N-hexane inhalation on the enantioselective pharmacokinetics and metabolism of verapamil in rats.
    Mateus FH; Lepera JS; Marques MP; Boralli VB; Lanchote VL
    Chirality; 2010 Jan; 22(1):29-34. PubMed ID: 19229957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1-Aminobenzotriazole modulates oral drug pharmacokinetics through cytochrome P450 inhibition and delay of gastric emptying in rats.
    Stringer RA; Weber E; Tigani B; Lavan P; Medhurst S; Sohal B
    Drug Metab Dispos; 2014 Jul; 42(7):1117-24. PubMed ID: 24727486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo use of the CYP inhibitor 1-aminobenzotriazole to increase long-term exposure in mice.
    Watanabe A; Mayumi K; Nishimura K; Osaki H
    Biopharm Drug Dispos; 2016 Sep; 37(6):373-8. PubMed ID: 27379984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the Complicated Nonlinear Pharmacokinetics of Orally Administered Telmisartan in Rats Using a Stable Isotope-IV Method.
    Minami K; Higashino H; Kataoka M; Togashi K; Mutaguchi K; Yamashita S
    J Pharm Sci; 2019 Aug; 108(8):2774-2780. PubMed ID: 30922857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human.
    Wang J; Xia S; Xue W; Wang D; Sai Y; Liu L; Liu X
    Eur J Pharm Sci; 2013 Nov; 50(3-4):290-302. PubMed ID: 23916407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increase in the systemic exposure of primary metabolites of Midazolam in rat arising from CYP inhibition or hepatic dysfunction.
    Hasegawa T; Nakanishi S; Minami K; Higashino H; Kataoka M; Shitara Y; Yamashita S
    Drug Metab Pharmacokinet; 2017 Feb; 32(1):69-76. PubMed ID: 28109684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Huang-Lian-Jie-Du-Decoction on pharmacokinetics of verapamil in rats.
    Xie SS; Hu N; Jing XY; Liu XD; Xie L; Wang GJ; Liu CH
    J Pharm Pharmacol; 2010 Apr; 62(4):440-7. PubMed ID: 20604832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of the suicide CYP450 inhibitor ABT for distinguishing absorption and metabolism processes in in-vivo pharmacokinetic screens.
    Caldwell GW; Ritchie DM; Masucci JA; Hageman W; Cotto C; Hall J; Hasting B; Jones W
    Eur J Drug Metab Pharmacokinet; 2005; 30(1-2):75-83. PubMed ID: 16010865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic interaction between verapamil and metoprolol in the dog. Stereochemical aspects.
    Murthy SS; Nelson WL; Shen DD; Power JM; Cahill CM; McLean AJ
    Drug Metab Dispos; 1991; 19(6):1093-100. PubMed ID: 1687016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronopharmacology of intravenous and oral modified release verapamil.
    Dilger K; Eckhardt K; Hofmann U; Kucher K; Mikus G; Eichelbaum M
    Br J Clin Pharmacol; 1999 Apr; 47(4):413-9. PubMed ID: 10233206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.